Litcius/Paper detail

Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model

Razieh Kebriaei, Katherine L. Lev, Kyle Stamper, Susan M. Lehman, Sandra Morales, Michael J. Rybak

2020Antimicrobial Agents and Chemotherapy27 citationsDOIOpen Access PDF

Abstract

This study aimed to test the efficacy of bacteriophage-antibiotic combinations (BACs) in vitro in 24-h time-kill settings and in ex vivo simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic models for 96 h. BACs prevented the development of bacteriophage resistance, while some bacteriophage resistance emerged in bacteriophage-alone treatments. In addition, BACs resulted in an enhancement of bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections.

Topics & Concepts

BacteriophagePharmacodynamicsMicrobiologyAntibioticsPharmacokineticsStaphylococcus aureusBiologyIn vivoIn vitroVirologyPharmacologyBacteriaEscherichia coliBiotechnologyGeneticsGeneBacteriophages and microbial interactionsBacterial Identification and Susceptibility TestingMicrobial infections and disease research
Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model | Litcius